Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab with Metronomic Chemotherapy and AI in Metastatic HER2+/HR+ Breast Cancer
NCT04941885Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inetetamab in breast cancer, sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04941885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941885.